SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.810
+0.190 (5.25%)
At close: Aug 25, 2026, 4:00 PM EDT
3.880
+0.070 (1.84%)
After-hours: Aug 25, 2026, 4:51 PM EDT

SAB Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
347178356330340
Market Cap Growth
1417.30%408.46%-44.79%113.36%-91.25%-
Enterprise Value
2497396627336
Last Close Price
3.813.743.796.885.9078.10

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-41.78----
PS Ratio
--26.4828.331.245.58
PB Ratio
1.481.181.351.110.968.81
P/TBV Ratio
1.611.181.351.110.968.81
P/OCF Ratio
-----170.89

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
--6.9129.321.145.51

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.020.040.180.100.190.22
Net Debt / Equity Ratio
-0.45-0.60-0.62-0.88-0.29-0.64
Net Debt / EBITDA Ratio
1.421.980.421.480.362.07
Net Debt / FCF Ratio
1.701.980.472.000.362.76
Asset Turnover
--0.020.030.360.88
Quick Ratio
8.939.132.615.231.371.56
Current Ratio
9.229.462.985.451.471.90
Return on Equity (ROE)
-11.27%14.96%-81.92%-95.51%-53.85%-44.21%
Return on Assets (ROA)
-33.46%-28.20%-41.86%-35.30%-27.37%-12.16%
Return on Capital Employed (ROCE)
-31.70%-30.20%-118.50%-52.10%-80.50%-24.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-6.29%7.46%-97.39%-66.52%-63.04%-5.05%
FCF Yield
-16.57%-25.67%-98.89%-39.91%-86.20%-2.64%
Buyback Yield / Dilution
-417.54%-562.28%-67.74%-26.86%-59.20%-1.21%
SEC Filings: 10-K · 10-Q